Publications in collaboration with researchers from Hospital Universitario Pío del Río Hortega (20)

2024

  1. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

    Blood, Vol. 144, Núm. 6, pp. 646-656

2023

  1. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

2020

  1. Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort

    Thrombosis and Haemostasis, Vol. 120, Núm. 3, pp. 437-448

  2. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia

    European Journal of Haematology, Vol. 104, Núm. 3, pp. 259-270

2019

  1. Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score

    Haemophilia, Vol. 25, Núm. 1, pp. 144-153

  2. Unraveling the effect of silent, intronic and missense mutations on VWF splicing: Contribution of next generation sequencing in the study of mRNA

    Haematologica, Vol. 104, Núm. 3, pp. 587-598

2018

  1. Role of multimeric analysis of von willebrand factor (VWF) in von willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project

    PLoS ONE, Vol. 13, Núm. 6

2017

  1. Molecular and clinical profile of von willebrand disease in Spain (PCM-EVW-ES): Comprehensive genetic analysis by next-generation sequencing of 480 patients

    Haematologica, Vol. 102, Núm. 12, pp. 2005-2014

  2. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970

2016

  1. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial

    Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899

  2. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

    European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302

  3. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

    Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84

  4. Molecular and clinical profile of von willebrand disease in spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm

    Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 40-50

2015

  1. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

2013

  1. Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis

    Leukemia, Vol. 27, Núm. 11, pp. 2149-2156

2012

  1. The Proliferation Index of Specific Bone Marrow Cell Compartments from Myelodysplastic Syndromes Is Associated with the Diagnostic and Patient Outcome

    PLoS ONE, Vol. 7, Núm. 8

2011

  1. Cell-cycle distribution of different cell compartments in normal versus reactive bone marrow: A frame of reference for the study of dysplastic hematopoiesis

    Cytometry Part B - Clinical Cytometry, Vol. 80 B, Núm. 6, pp. 354-361

2009

  1. Efficacy and safety of Liposomal cytarabine in lymphoma Patients with central nervous system involvement from lymphoma

    Cancer, Vol. 115, Núm. 9, pp. 1892-1898

2004

  1. Development of a new disease-specific quality-of-life questionnaire to adults living with haemophilia

    Haemophilia, Vol. 10, Núm. 4, pp. 376-382

2003

  1. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: No differences in cytogenetic responses

    Annals of Hematology, Vol. 82, Núm. 12, pp. 750-758